AACR 2021 | Upcoming advances in prostate cancer: PARPi, CDK4/6, lutetium PSMA therapy & CAR-T approaches

Arpit Rao, MD, University of Minnesota, Minnesota, MN, outlines the future landscape of treatment for patients with prostate cancer, including the use of the PARP inhibitor, rucaparib which will be evaluated in the Phase III CASPAR study (NCT04455750) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr Rao also highlights the use of abemaciclib, a CDK4/6 inhibitor in combination with androgen-receptor therapy as a potential therapeutic approach, as well as lutetium-PSMA therapies and the use of CAR T-cell therapies in prostate cancer. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.